ArticleRSC advances2021
Development of a gold-nanorod-based lateral flow immunoassay for a fast and dual-modal detection of C-reactive protein in clinical plasma samples.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- The preparation of two molecularly imprinted electrochemical sensors based on gold nanoparticles and glutaraldehyde and their application in protein detection.Mikrochimica acta · 2026Article
- Oxidase activity-enhanced manganese (III) oxide nanozyme grown in dendritic mesoporous silica nanoparticles for sensitive lateral flow immunoassay of C-reactive protein.Mikrochimica acta · 2026Article
- A Wearable In-Pad Diagnostic for the Detection of Disease Biomarkers in Menstruation Blood.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Current and future opportunities for lateral flow immunoassay strips based on tunable plasmonic properties of gold nanoparticles.Mikrochimica acta · 2025Review
- Plasmonic biosensors and actuators for integrated point-of-care diagnostics.Npj biosensing · 2025Review
- Effects on molecular interactions of hollow gold nanoparticles and antibody for sensitizing P24 antigen determination.RSC advances · 2024Article
- Article
- Sensitization Strategies of Lateral Flow Immunochromatography for Gold Modified Nanomaterials in Biosensor Development.International journal of nanomedicine · 2023Review
- Diagnoses Based on C-Reactive Protein Point-of-Care Tests.Biosensors · 2022Review
- Enhancement of the Detection Performance of Paper-Based Analytical Devices by Nanomaterials.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fast and simple detection of C-reactive protein (CRP) is highly significant for the diagnosis and prognosis of inflammatory or infectious diseases. Lateral flow immunoassay has the advantages of rapid detection, simple operation and low cost, but it is usually limited by the quantitative ability and speed of data extraction. Herein, a gold-nanorod-based lateral flow immunoassay was developed to rapidly detect CRP by simultaneously monitoring the colorimetric and temperature signals. In this method, anti-CRP antibody-modified gold nanorods (GNRs) were designed as colorimetric and photothermal conversion probes. A mouse anti-CRP monoclonal antibody and goat anti-mouse IgG were used as test and control lines, respectively. Then, a lateral flow immunochromatographic strip was constructed by a sandwich-type method for detecting CRP by introducing antibody-modified GNRs, and this procedure needed less than 15 min. Finally, the detection signals can be directly observed by eyes and directly read using a thermal imager. The as-synthesized GNR showed high photothermal conversion efficiency (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.